• Mashup Score: 0

    Hispanic children with high-risk neuroblastoma had worse survival outcomes than other children with the disease despite receiving treatment on clinical trials with standardized protocols, according to study results.Researchers observed the disparities even after controlling for disease-related factors.

    Tweet Tweets with this article
    • #ChildhoodCancerAwarenessMonth Hispanic children with high-risk #neuroblastoma had worse survival despite receiving standard therapy. https://t.co/vLTKKgHlt4 #pediatriconcology #ethnicdisparity @DanaFarber @UChicagoMed #ASCO22 #HispanicHeritageMonth #MedTwitter #Oncology

  • Mashup Score: 0

    CHICAGO — Combining brentuximab vedotin with a chemotherapy regimen as first-line therapy conferred an objective response in 88% of younger patients with newly diagnosed advanced-stage classical Hodgkin lymphoma, study results show.Data from the phase 1/phase 2 study presented at ASCO Annual Meeting suggest that the regimen — already FDA-approved for the same indication as first-line

    Tweet Tweets with this article
    • #ChildhoodCancerAwarenessMonth #BrentuximabVedotin w/ chemo as first-line therapy effective in 88% of younger patients with advanced-stage #Hodgkinlymphoma. https://t.co/5SLyUVOYgF #lymphoma #pediatriconcology @CincyChildrens @SeagenGlobal